Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Celltrion (068270) – Provisional Sales Results / 2024-05-09

Posted on May 9, 2024August 6, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) – Provisional Sales Results / 2024-05-09

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Celltrion reported its provisional Q1 2024 separate financial results, recording revenue of approximately KRW 638.2B and operating profit of approximately KRW 28.8B, representing a 102.70% QoQ increase in revenue.

📊 [Key Disclosure Details & Financial Highlights]

  1. Q1 2024 Performance (Separate Basis)
  • Revenue: KRW 638.245B (+102.70% QoQ, +19.17% YoY)
  • Operating Profit: KRW 28.785B (+11.38% QoQ, -84.48% YoY)
  • Profit Before Income Tax Expense: KRW 49.327B (+601.36% QoQ, -77.00% YoY)
  • Net Profit: KRW 60.933B (+112.97% QoQ, -64.55% YoY)
  1. Q1 2024 Cumulative Performance (Separate Basis)
  • Revenue: KRW 638.245B (+19.17% YoY)
  • Operating Profit: KRW 28.785B (-84.48% YoY)
  • Profit Before Income Tax Expense: KRW 49.327B (-77.00% YoY)
  • Net Profit: KRW 60.933B (-64.55% YoY)
  1. Historical Comparison Figures
  • Q4 2023: Revenue KRW 314.866B / Operating Profit KRW 25.843B / Net Profit KRW 28.611B
  • Q1 2023: Revenue KRW 535.580B / Operating Profit KRW 185.523B / Net Profit KRW 171.893B
  1. Information Provision Details
  • Provider: Celltrion IR Team
  • Target: Domestic and international investors, media, etc.
  • Date: 2024-05-09
  • Contact: IR Department (+82-1661-8722)
  • Note: Figures are based on Celltrion’s separate financial statements and are provisional, subject to change based on the final external audit results.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Comparison Between Separate and Consolidated Results and Verification of Audited Figures

This disclosure presents provisional operating results on a separate financial statement basis. Comparing these numbers with the consolidated results that include subsidiaries, as well as verifying final audited figures, is important for understanding the company’s overall financial health and comprehensive earnings performance. Detailed updates can be verified in subsequent disclosures and upcoming periodic reports (Quarterly, Half-Yearly, or Annual Reports).

📢 Disclaimer & Source Notice

Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Wonik IPS (240810) – Consolidated Financial Results (Provisional) / 2024-05-09
Next Post: [Disclosure] Jusung Engineering(036930) – Investment Caution Notice on Stock Futures and Options / 2024-05-10

Related Posts

[Disclosure] Samsung Biologics (207940) – Provisional Operating Performance (Fair Disclosure) / 2025-10-28 Disclosures
[Disclosure] SK hynix(000660) – Change in Chief Executive Officer (CEO) / 2024-03-27 Disclosures
[Disclosure] Jusung Engineering (036930) – Investor Relations (IR) Presentation / 2025-08-25 Semiconductors
[Disclosure] Hanwha Ocean (042660) – (Correction) Single Sales/Supply Contract / 2024-03-21 Disclosures
[Disclosure] Celltrion (068270) – Domestic (MFDS) Marketing Authorization for Stoboclo & Osenvelt (CT-P41, Prolia & Xgeva Biosimilar) / 2024-11-21 Disclosures
[Disclosure] PSK Holdings (031980) – Report on Reason for Holding Shareholders’ Meeting on Peak Concentration Day / 2024-02-07 Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Aerospace (012450) – Decision on Convening General Meeting of Shareholders / 2026-08-07August 7, 2026
  • [Disclosure] Hanwha Aerospace (012450) – Setting of Record Date for Shareholder Register Closure / 2026-08-07August 7, 2026
  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme